Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen

cafead

Administrator
Staff member
  • cafead   Dec 03, 2019 at 12:22: AM
via Swiss drugmaker Novartis's (NYSE: NVS) $9.7 billion takeover of The Medicines Company (NASDAQ: MDCO) gives the former ownership of an investigational cardiovascular drug called inclisiran. And that may mean trouble for Amgen (NASDAQ: AMGN) and its heart drug Repatha, which hasn't lived up to blockbuster hopes.

article source